Data Characteristics for This Category
Peptide drug clinical trial data originates from multiple sources. These include in vitro cell experiment reports, animal pharmacodynamics studies, toxicology assessments, preclinical research data, and published literature and databases. Data update frequencies vary. Clinical trial progress information may update weekly, while basic research data has a longer update cycle. Document structures are diverse. They include structured tabular data (e.g., subject baseline characteristics, laboratory indicators), semi-structured clinical reports (e.g., adverse event records, subject visit records), and unstructured research papers. Fields and units are highly specialized. Examples include peptide sequence, molecular weight, half-life (units hours, days), dosage (units mg/kg, μg/kg), biological activity (units nM, IC50), and various biomarker concentrations (units ng/mL, pg/mL).
Constraints Imposed by These Characteristics on "Multi-Turn Conversations and Prompts"
The complexity of peptide drug sequences and their diverse modifications require prompts to precisely describe specific peptide structures and functions, avoiding generalization. Key pharmacokinetic/pharmacodynamic parameters like half-life and biological activity require precise numerical matching and range evaluation. This constrains the dialogue model's ability to understand numbers and units. Clinical trial data involves many medical terms and abbreviations. Prompts must accurately parse these and guide the model through multi-turn questions to clarify ambiguous concepts. Varying update frequencies across data sources mean the model must identify information timeliness when answering, avoiding outdated data. The ability to interpret unstructured text determines if the model can extract critical adverse event information or subject inclusion/exclusion criteria from clinical reports and incorporate it into pre-screening decisions.
Configuration Settings
| Configuration Item | Suggested Value | Rationale |
|---|---|---|
maxContext | 2000 characters | Peptide sequences and clinical trial descriptions are often long. A sufficiently long context window maintains dialogue coherence. |
Chunk size (Segment Length) | 500 characters | Clinical reports have high content density. Shorter segment lengths improve recall precision and prevent key information from being diluted. |
Recall count (Number of Retrieved Items) | Top 8 | Clinical pre-screening involves multiple factors. Increasing the number of retrieved items covers more potential inclusion/exclusion criteria and subject characteristics. |
Similarity threshold (Similarity Threshold) | 0.75 | This ensures retrieved documents are highly relevant to the user query, filtering out irrelevant or low-relevance clinical trial records. |
Rerank result count (Number of Reranked Items) | 3 | This further refines the most relevant entries from highly similar documents, preventing the model from processing excessive redundant information. |
temperature | 0.3 | Clinical pre-screening requires rigorous and accurate answers. A lower temperature value helps generate more deterministic results. |
Three Common Mistakes
- A reply like "Cannot find research related to peptide sequence
XYZ" appears in the conversation. This may be due to minor differences in the peptide sequence or the database not including that specific modification. - The user asks about "adverse event severity level," and the model returns empty. This happens because adverse event descriptions in clinical reports are unstructured text and were not correctly extracted and tagged.
- During pre-screening, the model fails to identify a subject's age of
70 yearsas an inclusion/exclusion criterion. This is because age field units were improperly handled or age-related rules were not effectively encoded.
How to Confirm Correct Configuration
- Conduct multi-turn questioning for peptide sequences of varying complexity. Verify the model accurately identifies and associates them with corresponding preclinical research data.
- Simulate subject profiles containing multiple laboratory indicators and adverse event descriptions. Check if the model correctly assesses compliance with inclusion/exclusion criteria.
- Use queries containing specific pharmacokinetic parameters (e.g.,
half-life > 24 hours). Check if the model can perform precise screening based on numerical values and units.
Note: The values provided are common starting points. Measure them against your own samples for optimal performance.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.